Author:
Sloan Derek D.,Lam Chia-Ying Kao,Irrinki Alivelu,Liu Liqin,Tsai Angela,Pace Craig S.,Kaur Jasmine,Murry Jeffrey P.,Balakrishnan Mini,Moore Paul A.,Johnson Syd,Nordstrom Jeffrey L.,Cihlar Tomas,Koenig Scott
Publisher
Public Library of Science (PLoS)
Subject
Virology,Genetics,Molecular Biology,Immunology,Microbiology,Parasitology
Reference95 articles.
1. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial;E DeJesus;Lancet,2012
2. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study;F Raffi;Lancet,2013
3. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials;PE Sax;Lancet,2015
4. Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy;TW Chun;Nat Med,2000
5. Randomized, controlled trial of therapy interruption in chronic HIV-1 infection;E Papasavvas;PLoS Med,2004
Cited by
86 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献